Insights

Gathering insights about Genus…

Similar companies to Genus

Genus Tech Stack

Genus uses 8 technology products and services including Microsoft Clarity, RSS, WordPress, and more. Explore Genus's tech stack below.

Microsoft Clarity
Analytics
RSS
Content Management System
WordPress
Content Management System
Squarespace Commerce
E-commerce
Priority Hints
Performance
Cloudflare Bot Management
Security
Google Tag Manager
Tag Management
Adobe Fonts
Web Fonts

Media & News

Short Interest in Agenus Inc. (NASDAQ:AGEN) Rises By 56.5%
Agenus Inc. (NASDAQ: AGEN - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,774,043 shares, an increase of 56.5% from the November 30th total of 1,772,528 shares. Approximately 8.6% of the company's stock are sold short. Based
Dec 29, 2025 | www.defenseworld.net
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC). The peer-reviewed manuscript titled, “Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer,” i.
Dec 23, 2025 | www.businesswire.com
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Dec 04, 2025 | seekingalpha.com
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer. The session will be moderated by Garo Armen, PhD, Fo.
Nov 19, 2025 | www.businesswire.com
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (.
Nov 18, 2025 | www.businesswire.com
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
Nov 10, 2025 | www.zacks.com
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory Fr.
Nov 10, 2025 | www.businesswire.com

Genus's Email Address Formats

Genus uses at least 2 format(s):

Genus Email Formats	Example	Percentage
First.Last@genus.biz	John.Doe@genus.biz	100%

Frequently Asked Questions

What is Genus's stock symbol?

Genus is a publicly traded company; the company's stock symbol is AGEN.

What is Genus's official website and social media links?

Genus's official website is genus.co and has social profiles on LinkedIn.

What is Genus's NAICS code?

Genus's NAICS code is 5112 - Software Publishers.

How many employees does Genus have currently?

As of December 2025, Genus has approximately 109 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Ceo: E. H.Chief Operating Officer: L. H.Chief Technology Officer: J. T. A.. Explore Genus's employee directory with LeadIQ.

What industry does Genus belong to?

Genus operates in the Software Development industry.

What technology does Genus use?

Genus's tech stack includes Microsoft ClarityRSSWordPressSquarespace CommercePriority HintsCloudflare Bot ManagementGoogle Tag ManagerAdobe Fonts.

What is Genus's email format?

Genus's email format typically follows the pattern of First.Last@genus.biz. Find more Genus email formats with LeadIQ.

When was Genus founded?

Genus was founded in 1995.

Genus

Q: What is Genus's official website and social media links?

Genus's official website is genus.co. Genus has social profiles on LinkedIn.

Q: How many employees does Genus have currently?

Genus has approximately 109 employees.

Q: What technology does Genus use?

Genus's tech stack includes Cart Functionality, Squarespace Commerce, PHP, Google Tag Manager, Cloudflare Bot Management.

Software DevelopmentAkershus, Norway51-200 Employees

Genus AS is a Norwegian software company offering a powerful no-code platform for enterprise solutions. We specialize in empowering industries such as financial services, banking, insurance, and resource management with tailored no-code applications.

We prioritize data security and regulatory compliance across multiple countries, empowering our customers to improve operational efficiency while safeguarding sensitive information.

Founded in 1995, Genus has been at the forefront of streamlining workflows through automation and digitalization. Our platform offers flexible solutions that can be updated in minutes, seamlessly integrates with existing systems, enhances data governance, and enables rapid adaptation to market changes—ensuring your business remains competitive in a dynamic landscape.